A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe hidradenitis suppurativa

Recruiting

99 years and younger

All

Phase N/A

1 Location

Brief description of study

The purpose of this study is to determine if the research drug, sonelokimab, is effective in reducing the signs and symptoms of HS in people with moderate to severe disease, compared to placebo. Procedures include Vital signs, Physical Exam, Medical History, Blood and Urine tests, EKG and electronic questionnaires.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

TBD

Updated on 09 Oct 2024. Study ID: 856683

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).